CN115955979B - Cereblon结合化合物、其组合物及其用于治疗的方法 - Google Patents

Cereblon结合化合物、其组合物及其用于治疗的方法

Info

Publication number
CN115955979B
CN115955979B CN202180044305.0A CN202180044305A CN115955979B CN 115955979 B CN115955979 B CN 115955979B CN 202180044305 A CN202180044305 A CN 202180044305A CN 115955979 B CN115955979 B CN 115955979B
Authority
CN
China
Prior art keywords
trans
cyclohexyl
trifluoromethyl
oxo
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180044305.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115955979A (zh
Inventor
M·D·亚历山大
M·D·科雷亚
D·达尔维
V·H·S·格兰特
J·汉森
R·L·哈里斯三世
E·J·霍恩
D·黄
C·梅恩
S·诺里斯
V·普兰特文-克雷尼茨基
J·J·萨皮恩扎
L·泰赫拉尼
B·W·怀特菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinji
Original Assignee
Xinji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinji filed Critical Xinji
Publication of CN115955979A publication Critical patent/CN115955979A/zh
Application granted granted Critical
Publication of CN115955979B publication Critical patent/CN115955979B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN202180044305.0A 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法 Active CN115955979B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24
US63/043,612 2020-06-24
PCT/US2021/038625 WO2021262812A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
CN115955979A CN115955979A (zh) 2023-04-11
CN115955979B true CN115955979B (zh) 2025-12-05

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044305.0A Active CN115955979B (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法

Country Status (9)

Country Link
US (2) US11739075B2 (https=)
EP (1) EP4171568B1 (https=)
JP (1) JP7778095B2 (https=)
KR (1) KR20230027213A (https=)
CN (1) CN115955979B (https=)
AR (1) AR122725A1 (https=)
ES (1) ES3048462T3 (https=)
TW (1) TW202216681A (https=)
WO (1) WO2021262812A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
JP2024534223A (ja) 2021-09-01 2024-09-18 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｂｃｌ－２ファミリータンパク質を分解する化合物及びその医薬的な応用
AU2023278399A1 (en) 2022-06-02 2024-12-19 Xizang Haisco Pharmaceutical Co., Ltd. Compound for inhibiting or degrading bcl6 and use thereof in pharmaceutics
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 ３－苯基丙基胺衍生物
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1492869A (zh) * 2001-02-23 2004-04-28 ���ʵ�ҩƷ��˾ 三环雄激素受体调节剂化合物和方法
CN103842348A (zh) * 2011-10-13 2014-06-04 伊莱利利公司 选择性雄激素受体调节剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1492869A (zh) * 2001-02-23 2004-04-28 ���ʵ�ҩƷ��˾ 三环雄激素受体调节剂化合物和方法
CN103842348A (zh) * 2011-10-13 2014-06-04 伊莱利利公司 选择性雄激素受体调节剂

Also Published As

Publication number Publication date
CN115955979A (zh) 2023-04-11
EP4171568B1 (en) 2025-08-27
US11739075B2 (en) 2023-08-29
WO2021262812A1 (en) 2021-12-30
JP7778095B2 (ja) 2025-12-01
EP4171568A4 (en) 2024-07-24
EP4171568A1 (en) 2023-05-03
TW202216681A (zh) 2022-05-01
US12227490B2 (en) 2025-02-18
ES3048462T3 (en) 2025-12-10
US20210403453A1 (en) 2021-12-30
KR20230027213A (ko) 2023-02-27
JP2023531709A (ja) 2023-07-25
AR122725A1 (es) 2022-09-28
US20230348431A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN115955979B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN115835866B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN115968293B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN117561249A (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
EP4359404A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US20250100995A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant